Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Go back to Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 101.89 +3.67 (3.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.22 | 52 Week High | $118.49 | |||
| Open | $99.79 | 52 Week Low | $55.00 | |||
| Day High | $102.26 | P/E | N/A | |||
| Day Low | $99.79 | EPS | $-0.56 | |||
| Volume | 300,779 | |||||
